Bone-biomarkers of Spinal Cord Injury Patients

Patients with spinal cord injury have a high prevalence of osteoporosis due to chronic skeletal unloading. Recently, various treatment drugs for osteoporosis have been developed. In particular, romosozumab, a sclerostin inhibitor, has been reported to have a high therapeutic effect as an inhibitor of bone resorption while promoting bone formation. However, there are a few research concerning sclerostin of spinal cord injuries patients. Therefore we want to analyze the change of sclerostin as well as factors indicating bone formation and absorption marker in spinal cord injury patient.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Spinal Cord Injuries Bone Diseases Bone Diseases, Metabolic Bone Resorption Central Nervous System Diseases Metabolic Diseases Musculoskeletal Diseases Nervous System Diseases Nutritional and Metabolic Diseases Osteoporosis Sclerosteosis Spinal Cord Diseases Trauma, Nervous System Wounds and Injuries

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Yeungnam University Hospital

Daegu, 42415, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

spinal cord injury patients
Functional ambulatory category index of 3 or less

Exclusion criteria

history of using bone absorption medication within the effective period

Treatment and study plan

Primary outcomes

Serum sclerostin level

Time frame: 1 year

Serum sclerostin level in spinal cord injury patients

Sponsors and collaborators

Lead sponsor

Yeungnam University Hospital

Other

Registry information

Official study title

Changes of Bone-biomarker According to the Severity of Spinal Cord Injury.

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: May 27, 2020
Registry last updated: Aug 31, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed